According to our research, BDCA3+ (CD141+) DCs exhibit the strongest cross-presentation ability, followed by CD1c+ DCs, while CD16+ DCs and MoDCs cannot present antigens derived from necrotic lung cancer cells. The gene discussed is CD1C; the disease is lung carcinoma.